Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Paraparesis, Tropical Spastic 1Neuritis 1Leukemia-Lymphoma, Adult T-Cell 1Infections 1HTLV-I Infections 1Epstein-Barr Virus Infections 1

Interventions

Valganciclovir 3Rituximab 3Cisplatin 3Vincristine 2Radiotherapy, Intensity-Modulated 2Prednisone 2Matrix-M 2Gemcitabine 2Etoposide 2Doxorubicin 2Cyclophosphamide 2pomalidomide 1dehydroftorafur 1brincidofovir 1Watchful Waiting 1Valacyclovir 1Tomography, X-Ray Computed 1Tenofovir 1Tegafur 1Taxes 1Platinum 1Phantoms, Imaging 1Paclitaxel 1Nivolumab 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Mitomycin 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Interferons 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epstein-Barr Virus Infections × Tenofovir × 1 year × Clear all
NCT07133776 2025-08-21

Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.

The Affiliated Hospital of Xuzhou Medical University

Phase 1/2 Not yet recruiting
30 enrolled

Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡